CN1303084C - 新型粗榧生物碱、其制备方法和其在治疗癌症、白血病、包括耐受通常的化学治疗剂的寄生物在内的寄生物及作为反向治疗剂的应用 - Google Patents

新型粗榧生物碱、其制备方法和其在治疗癌症、白血病、包括耐受通常的化学治疗剂的寄生物在内的寄生物及作为反向治疗剂的应用 Download PDF

Info

Publication number
CN1303084C
CN1303084C CNB00820036XA CN00820036A CN1303084C CN 1303084 C CN1303084 C CN 1303084C CN B00820036X A CNB00820036X A CN B00820036XA CN 00820036 A CN00820036 A CN 00820036A CN 1303084 C CN1303084 C CN 1303084C
Authority
CN
China
Prior art keywords
dichloromethane
mmol
och
harringtonine
aqueous layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB00820036XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1474821A (zh
Inventor
J-P·罗宾
R·达尔
F·德鲁耶
J－P·马里耶
N·拉多塞维克
J·罗宾
K·苏绍
P·巴塔伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemical Gene Pharmaceutical Co ltd
Ivax International Ltd
Teva Pharmaceuticals International GmbH
Original Assignee
Stijen Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stijen Pharmaceutical filed Critical Stijen Pharmaceutical
Publication of CN1474821A publication Critical patent/CN1474821A/zh
Application granted granted Critical
Publication of CN1303084C publication Critical patent/CN1303084C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB00820036XA 2000-10-17 2000-10-17 新型粗榧生物碱、其制备方法和其在治疗癌症、白血病、包括耐受通常的化学治疗剂的寄生物在内的寄生物及作为反向治疗剂的应用 Expired - Fee Related CN1303084C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/001593 WO2002032904A1 (en) 2000-10-17 2000-10-17 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents

Publications (2)

Publication Number Publication Date
CN1474821A CN1474821A (zh) 2004-02-11
CN1303084C true CN1303084C (zh) 2007-03-07

Family

ID=11003995

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB00820036XA Expired - Fee Related CN1303084C (zh) 2000-10-17 2000-10-17 新型粗榧生物碱、其制备方法和其在治疗癌症、白血病、包括耐受通常的化学治疗剂的寄生物在内的寄生物及作为反向治疗剂的应用

Country Status (12)

Country Link
US (1) US6579869B1 (enExample)
EP (1) EP1328527B1 (enExample)
JP (1) JP4837233B2 (enExample)
CN (1) CN1303084C (enExample)
AT (1) ATE319714T1 (enExample)
AU (1) AU7940500A (enExample)
CA (1) CA2426103A1 (enExample)
DE (1) DE60026557T2 (enExample)
DK (1) DK1328527T3 (enExample)
ES (1) ES2258024T3 (enExample)
PT (1) PT1328527E (enExample)
WO (1) WO2002032904A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285546B2 (en) * 2000-10-17 2007-10-23 Stragen Pharma S.A. Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
WO2004009092A1 (en) 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
WO2009148654A2 (en) 2008-03-03 2009-12-10 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
US20120022250A1 (en) * 2009-03-11 2012-01-26 Jean-Pierre Robin Process for preparing cephalotaxine esters
CN102304132B (zh) * 2011-07-12 2015-01-28 南开大学 高效高立体选择性半合成三尖杉酯类生物碱的方法
JP6068472B2 (ja) * 2011-08-18 2017-01-25 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． アミノ化ホモハリントニン誘導体、その調製方法及び使用
CN103687859B (zh) * 2011-08-18 2016-08-17 杭州本生药业有限公司 高三尖杉酯碱的胺化衍生物、及其制备方法和应用
CN102675327B (zh) * 2012-03-01 2014-12-10 南开大学 三尖杉酯碱类似物及制备方法和应用
CN104293855A (zh) * 2014-10-15 2015-01-21 中国计量学院 脐孢木霉菌转化株在提高木霉素产量中的应用
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CN106866690B (zh) * 2015-12-10 2019-10-11 南开大学 三尖杉酯类生物碱、其制备方法和用途
CN109111459B (zh) * 2017-06-22 2021-10-29 南华大学 含水杨酸三尖杉碱酯衍生物、制造方法及其用途
CN108378049A (zh) * 2018-05-02 2018-08-10 孙利嫚 一种含有粗榧生物碱和甲氧虫酰肼的农药组合物
CN119968374A (zh) * 2022-09-22 2025-05-09 南开大学 三尖杉酯碱类衍生物及其药物组合物、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048894A1 (en) * 1998-03-20 1999-09-30 Oncopharm Corporation Novel cephalotaxane derivatives and process for their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048894A1 (en) * 1998-03-20 1999-09-30 Oncopharm Corporation Novel cephalotaxane derivatives and process for their preparation

Also Published As

Publication number Publication date
PT1328527E (pt) 2006-06-30
HK1063183A1 (en) 2004-12-17
DK1328527T3 (da) 2006-07-17
CA2426103A1 (en) 2002-04-25
DE60026557T2 (de) 2006-12-28
ES2258024T3 (es) 2006-08-16
CN1474821A (zh) 2004-02-11
AU7940500A (en) 2002-04-29
US6579869B1 (en) 2003-06-17
JP2004511560A (ja) 2004-04-15
DE60026557D1 (de) 2006-05-04
EP1328527A1 (en) 2003-07-23
JP4837233B2 (ja) 2011-12-14
WO2002032904A1 (en) 2002-04-25
ATE319714T1 (de) 2006-03-15
EP1328527B1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
CN1303084C (zh) 新型粗榧生物碱、其制备方法和其在治疗癌症、白血病、包括耐受通常的化学治疗剂的寄生物在内的寄生物及作为反向治疗剂的应用
CN1277828C (zh) 哌嗪衍生物
CN1139592C (zh) 喜树碱衍生物，其制备用途以及中间体
CN1956722A (zh) 含有新的美登素类的改进的细胞毒剂
CN1220692C (zh) 三尖杉烷衍生物的制备方法
CN1043766C (zh) 吲哚衍生物及其制法和它们在制备药物中的应用
CN1158614A (zh) 新型化合物及其制法和抗肿瘤剂
CN1781920A (zh) 多环鸟嘌呤磷酸二酯酶v抑制剂
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN1492872A (zh) 作为雄激素受体调节剂化合物的三环喹啉酮和三环喹啉
CN1211244A (zh) 根赤壳菌素衍生物
CN1202116C (zh) 除虫菌素衍生物
CN101039916A (zh) 作为大电导钙激活k通道开启剂的咪唑衍生物
CN1317277C (zh) 苯并呋喃衍生物及其作为药物制剂的应用
CN1053184C (zh) 新的乌头碱型化合物及解热、镇痛、抗炎症药
CN1653071A (zh) 对耐药菌有效的10－(3－环丙基氨基甲基－1－吡咯烷基)吡啶并苯并噁嗪羧酸衍生物
CN1031941C (zh) 氟代乙基喜树碱衍生物的制备方法
CN1906200A (zh) 新化合物
HK1063183B (en) New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents
CN1870896A (zh) 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物
CN1304380C (zh) 苯并[a]吩嗪－11－酰胺衍生物及它们作为拓扑异构酶Ⅰ和Ⅱ的联合抑制剂的用途
CN1617874A (zh) 六环化合物
HK1045514A1 (en) Optically pure camptothecin analogues and composition and use thereof
CN1297556C (zh) 苯并[b]色烯并－萘啶－7－酮和吡喃并[2＇,3＇:7,8]喹啉并[2,3－b]喹喔啉－7－酮化合物、其制备方法及药用组合物
CN1656066A (zh) 联合药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1063183

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: STRAGEN PHARMACEUTICAL COMPANIES

Free format text: FORMER OWNER: CANCER MEDICINE STOCK CO., LTD.

Effective date: 20050902

Owner name: CANCER MEDICINE STOCK CO., LTD.

Free format text: FORMER OWNER: ONCOPHARM CORP.

Effective date: 20050902

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20050902

Address after: Geneva, Switzerland

Applicant after: Stijen Pharmaceutical

Address before: le mans

Applicant before: Oncology drug Co.

Effective date of registration: 20050902

Address after: le mans

Applicant after: Oncology drug Co.

Address before: Texas in the United States

Applicant before: Cancer drug Co.

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: CHEMICAL GENE PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: STEGINE PHARMACEUTICAL CO.,LTD.

Effective date: 20100115

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100115

Address after: Vitoria Australia

Patentee after: Chemical Gene Pharmaceutical Co.,Ltd.

Address before: Geneva, Switzerland

Patentee before: Stijen Pharmaceutical

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: Swiss Qiao Na

Patentee after: TEVA PHARMACEUTICALS INTERNATIONAL GmbH

Address before: La Perth, Switzerland

Patentee before: Ivax International Ltd.

Address after: New South Wales, Australia

Patentee after: Chemical Gene Pharmaceutical Co.,Ltd.

Address before: Vitoria Australia

Patentee before: Chemical Gene Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right

Effective date of registration: 20160831

Address after: La Perth, Switzerland

Patentee after: Ivax International Ltd.

Address before: New South Wales, Australia

Patentee before: Chemical Gene Pharmaceutical Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070307

Termination date: 20181017

CF01 Termination of patent right due to non-payment of annual fee